Trial results

Incretin Therapies in Obesity-related HFpEF

NCT07554638 on ClinicalTrials.gov · last registry update 2026-08-24

Recruiting now, toward 50 participants. Due to report April 2029, alongside 11 other tracked readouts that quarter. Primary outcome, as filed: Plasma volume. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is approved in the US, but not for heart failure — a registration here is not an approval, and most drugs tested in a new condition never get one for it. The registry entry has been edited 1 time since then.

Status

RECRUITING

Phase

P4

Drug

tirzepatide

Zepbound, Mounjaro

Sponsor

Columbia University

Sponsor type

Other

Enrollment

50

Started

2026-08-07

Primary completion

2029-04 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Plasma volume

Conditions studied

Heart Failure, Diastolic · Heart Failure With Preserved Ejection Fraction · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.